Clinical trials: Pulmonary Fibrosis, Idiopathic
Idiopathic Pulmonary Fibrosis
First Time in Human (FTIH) Study of GSK3008348 in Healthy Volunteers and Idiopathic Pulmonary Fibrosis Patients
GSK3008348 is an investigational drug, being developed by GlaxoSmithKline Research and Development Limited (the Sponsor, a pharmaceutical company based in the UK) for the treatment of Idiopathic Pulmonary Fibrosis (IPF).
- Trial name
- NCT02612051
- Testing
- GSK3008348 Nebuliser solution, GSK26346763: ([18F]-FBA-A20FMDV2) IV infusion
- Where
- United Kingdom
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease
Pilot Study of Nitrate-rich Beetroot Juice Supplementation in Patients With Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic pulmonary fibrosis (IPF) is a type of scarring (fibrotic) lung disease. Reduced exercise capacity is a key symptom experienced by patients.
- Trial name
- BEET-IPF (NCT06488638)
- Testing
- nitrate-rich beetroot juice (70ml with approx. 400 mg nitrate) twice a day for 3 days
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Idiopathic Pulmonary Fibrosis
Randomized, Crossover, Multi-Dose Pharmacokinetics of EXCL-100 Pirfenidone-Sustained Release Tablet and Esbriet in Healthy Volunteers
This is a randomized, open-label, 2-treatment, 2-period, crossover steady state study conducted to evaluate the comparative bioavailability/bioequivalence of pirfenidone after multi-dose administration of EXCL-100 at doses of…
- Trial name
- NCT05428150
- Testing
- Esbriet 267 MG Oral Capsule, EXCL-100, 600 MG Oral Tablet
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Excalibur Pharmaceuticals, Inc.
Idiopathic Pulmonary Fibrosis
A Drug-Drug Interaction Study of ENV-101 (Taladegib) on Nintedanib Pharmacokinetics in Healthy Subjects
The goal of this clinical trial is to learn about the potential effect of ENV-101 (taladegib) on the pharmacokinetics of nintedanib (an approved treatment for idiopathic pulmonary fibrosis) when the two compounds are dosed…
- Trial name
- NCT05817240
- Testing
- taladegib, nintedanib
- Where
- Australia
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Endeavor Biomedicines, Inc.
Chronic Obstructive Pulmonary Disease, Asthma
Impact of Air Pollution on Chronic Respiratory Diseases
The aim of this study is to evaluate the impact of air pollution on the occurrence and clinical course of chronic respiratory diseases, and discover new biomarkers from various devices such as CT images that can indicate the…
- Conditions
- Chronic Obstructive Pulmonary Disease, Asthma, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT03813810
- Testing
- Non
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Idiopathic Pulmonary Fibrosis
A Phase 1, Evaluate the Safety, Tolerability, and Pharmacokinetics of INS018_055 in Healthy Subjects
The sponsor is planning to conduct a Phase 1, randomized, double-blind, placebo-controlled, oral single and multiple ascending-doses, parallel group study to evaluate the safety, tolerability and PK of INS018_055 in healthy…
- Trial name
- NCT05154240
- Testing
- INS018_055
- Where
- New Zealand
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- InSilico Medicine Hong Kong Limited
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SRN001 in Healthy Korean and Caucasian Adult Males
To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of SRN001 in healthy adult volunteers.
- Trial name
- NCT07407543
- Testing
- SRN001, 0.9% sodium chloride (normal saline)
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- siRNAgen Therapeutics Inc.
Idiopathic Pulmonary Fibrosis
A Study to Evaluate the Safety, Tolerability, Pharmacokinetic Properties and Immunogenicity of 9MW3811 in Healthy Subjects
This is a single ascending dose study of 9MW3811, the primary objective of which is to evaluate the safety and tolerability of 9MW3811 in healthy adult participants.
- Trial name
- NCT05912049
- Testing
- 9MW3811 Injection
- Where
- China
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.
Cystic Fibrosis, Hemophilia A
Medication Adherence and Non-adherence in Adults With Rare Disease
The purpose of this study is to use the Medication Adherence Reasons Scale (MAR-Scale) to determine the extent of non-adherence to specific medications indicated to treat cystic fibrosis, hemophilia (A or B), idiopathic pulmonary…
- Conditions
- Cystic Fibrosis, Hemophilia A, Hemophilia B, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT04541875
- Testing
- MAR-Scale
- Volunteers
- healthy volunteers welcome
- Sponsor
- Xperiome
Idiopathic Pulmonary Fibrosis
Evaluation of the Value of 18F-Fluoromisonidazole (18F-FMISO) Positron Emission Tomography Hypoxia Imaging in Idiopathic Pulmonary Fibrosis
Idiopathic pulmonary fibrosis (IPF) is a rare, chronic, lethal disease of unknown etiology and with a variable course. There is currently no test in routine care that can assess both the anatomical and functional damage of the…
- Trial name
- FIPOXY (NCT05331729)
- Testing
- FMISO-PET Protocol
- Where
- France
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire Dijon
Idiopathic Pulmonary Fibrosis (IPF)
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
This is a Phase I stage to investigate the safety and tolerability of MG-S-2525 in healthy volunteers. The proposed trial consists of 3 study parts to be conducted at Tri-Service General Hospital and includes Single Ascending…
- Trial name
- NCT03650075
- Testing
- MG-S-2525
- Where
- Taiwan
- Volunteers
- 81 people, healthy volunteers welcome
- Sponsor
- Metagone Biotech Inc.
Diopathic Pulmonary Fibrosis, Pulmonary Fibrosis
The Safety, Tolerability, and Pharmacokinetic Study of SC1011 in Healthy Subjects.
The goal of this clinical trial is to learn about the safety, tolerability and pharmacokinetic profiles of SC1011,in health conditions.
- Trial name
- NCT06160440
- Testing
- SC1011
- Where
- China
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Guangzhou JOYO Pharma Co., Ltd
Idiopathic Pulmonary Fibrosis (IPF)
A Phase I Study of HW241045 in Healthy Subjects
This is a Phase I, randomized, double-blind, placebo-controlled study to assess the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD), and food effect (FE) of HW241045 in healthy participants.
- Trial name
- NCT07593690
- Testing
- HW241045 Formulation A, HW241045 Formulation B
- Where
- China
- Volunteers
- 102 people, healthy volunteers welcome
- Sponsor
- Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.
Idiopathic Pulmonary Fibrosis (IPF)
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
Drug discovery can take many years especially since most studies to measure effectiveness depend on clinical outcomes like pulmonary function tests and hospitalizations.
- Trial name
- NCT01718990
- Where
- United States
- Volunteers
- 110 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Idiopathic Pulmonary Fibrosis(IPF), Solid Tumor
Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Ascending Dose of ZSP1603 in Healthy Adults
The Primary objectives of this study are to evaluate the safety and tolerability of ZSP1603 and the Secondary objective is to estimate the pharmacokinetic (PK) parameters after orally administered once daily of ZSP1603.
- Trial name
- NCT03619616
- Testing
- ZSP1603 7.5 mg, ZSP1603 12.5 mg, ZSP1603 25 mg
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Guangdong Zhongsheng Pharmaceutical Co., Ltd.
Idiopathic Pulmonary Fibrosis (IPF)
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
The main objectives of this study are to characterize the PK of BMS-986278 after administration of a single dose of BMS-986278 alone or in combination with pirfenidone, as well as to characterize the PK of pirfenidone after…
- Trial name
- NCT03981094
- Testing
- BMS-986278, Pirfenidone
- Where
- United States
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Idiopathic Pulmonary Fibrosis
Using MRI to Visualize Regional Therapy Response in Idiopathic Pulmonary Fibrosis
The purpose of this study is to determine whether magnetic resonance imaging (MRI) using inhaled hyperpolarized 129Xe gas, and conventional contrast can help visualize impaired lung function and detect changes over time in…
- Trial name
- NCT02478268
- Testing
- Hyperpolarized 129-Xenon gas, MRI
- Where
- 2 sites in United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Bastiaan Driehuys
Idiopathic Pulmonary Fibrosis
Study To Investigate The Potential DDI Between HEC585 And Pirfenidone/Nintedanib In Healthy Subjects
A single-center, open-label study designed to assess the drug-drug interaction of HEC585 and pirfenidone in healthy male and female subjects.
- Trial name
- NCT07588646
- Testing
- HEC585, Nintedanib, Pirfenidone
- Where
- China
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis
Toward Self-management in ILD
Treating and caring for people with long term conditions accounts for a substantial proportion of health care resources. Self-management is advocated as a mechanism that can empower service users with long term conditions to…
- Conditions
- Interstitial Lung Disease, Idiopathic Pulmonary Fibrosis, Connective Tissue Related ILD, Chronic Hypersensitivity Pneumonitis
- Trial name
- NCT03300583
- Testing
- Focus groups, Semi-structured interviews
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Kingston University
Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis
Detection of Integrin avb6 in IPF, PSC, and COVID19 Using PET/CT
Detection of Integrin avb6 in Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, and Coronavirus Disease 2019 with [18F]FP-R01-MG-F2 with PET/CT
- Conditions
- Idiopathic Pulmonary Fibrosis, Primary Sclerosing Cholangitis, Covid19 Pneumonia
- Trial name
- NCT03183570
- Testing
- [18F]FP-R01-MG-F2
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Stanford University